Investigator Initiated Observational Study of Intravitreal Aflibercept Injection in Subjects With Diabetic Macular Edema Previously Treated With Ranibizumab or Bevacizumab
Latest Information Update: 03 Apr 2023
Price :
$35 *
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions; Therapeutic Use
- Acronyms SwapTwo
- 25 Jan 2021 Status changed from recruiting to completed.
- 29 Jan 2020 Planned End Date changed from 1 Dec 2018 to 1 Dec 2020.
- 29 Jan 2020 Planned primary completion date changed from 1 Nov 2018 to 1 Nov 2020.